Last reviewed: June 5, 2026

Last updated: June 5, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated consistent weight loss across multiple clinical trials. A landmark 2021 study published in the New England Journal of Medicine found participants lost an average of 15.3 kg (10.2% of baseline weight) when using semaglutide 2.4 mg weekly. Understanding realistic outcomes and how individual factors shape your results helps set achievable goals before starting treatment.

Average Weight Loss on Semaglutide: Clinical Trial Evidence

The STEP trials followed over 4,500 adults with obesity for 68 weeks. Participants receiving weekly semaglutide 2.4 mg injections lost between 15–22% of their starting body weight, compared to 2–3% in the placebo group. A 200-pound person, for example, might expect to lose 30–44 pounds over the treatment period. These results represent some of the most significant weight reductions ever achieved with a single medication in obesity research.

Response rates vary based on genetics, metabolism, and adherence. Some participants experience rapid initial weight loss in the first 8–12 weeks, while others show steady, gradual decline. Most weight loss occurs in the first 6 months of consistent use, after which the rate of loss typically stabilizes. Individual results depend on dose escalation, dietary choices, physical activity, and underlying metabolic factors that PlexusDx evaluates through its Precision Peptide Genetic Test.

How Genetics Influence Your Personal Semaglutide Response

Not all bodies respond identically to semaglutide because genetic variations affect how your cells sense hunger signals and process glucose. Key variants in the GLP1R gene (like rs6923761) and FTO gene (rs9939609) influence appetite regulation and fat storage patterns. PlexusDx analyzes 14 metabolic pathways and 49 peptides to map how your unique genetic profile shapes response to GLP-1 therapy.

The Precision Peptide Genetic Test ($99 add-on after your first month) identifies whether you carry genetic predispositions that enhance or slow semaglutide effectiveness. Patients with certain GLP1R variants often experience faster satiety and greater weight loss, while FTO variants may predict slower initial response but sustained long-term results. This personalized insight allows PlexusDx to optimize your starting dose and escalation schedule, maximizing outcomes while keeping your price flat—your dose may go up, but your monthly cost stays at $149.

Dose Escalation and Weight Loss Trajectory

Semaglutide dosing follows a gradual escalation protocol designed to minimize side effects while building effectiveness. Most patients begin at 0.25 mg weekly and increase by 0.25 mg every four weeks until reaching the therapeutic dose of 2.4 mg. Faster escalation can trigger nausea and appetite suppression; slower escalation allows your body to adapt and may extend the timeline to maximum weight loss. PlexusDx compounded semaglutide injections begin at $149 per month, and your dose adjustments never change that price.

Weight loss typically accelerates as you reach higher doses. Patients at 1.7 mg often report noticeable appetite reduction and early weight loss of 5–10 pounds per month. Once stabilized at 2.4 mg, the rate often slows to 1–3 pounds weekly as your body reaches a new set point. Some individuals plateau after 6–12 months; others continue losing weight for 18+ months. Combining semaglutide with modest dietary changes (reduced calorie intake, increased protein) and regular movement strengthens results.

Realistic Weight Loss Timeline and Long-Term Maintenance

The first 4–8 weeks often bring modest weight loss of 2–5 pounds as your appetite begins to shift. Weeks 8–16 typically accelerate this loss to 3–5 pounds weekly as your dose approaches therapeutic levels. The peak weight-loss window spans months 3–6, where cumulative loss may reach 15–30 pounds. After 6 months, the rate gradually plateaus as your body adapts to the medication and reaches a new equilibrium. This trajectory reflects your body's natural metabolic response rather than a failure of the medication.

Weight regain occurs in some patients after stopping semaglutide because appetite hormones normalize and hunger signals return to baseline. Clinical data suggests maintaining treatment sustains weight loss long-term, while discontinuation leads to 50–70% weight regain over one to two years. PlexusDx supports continuous, affordable access with no membership fees, HSA/FSA eligibility, and availability across all 50 states, making sustained treatment feasible for more patients seeking durable results.

Factors That Affect Your Individual Weight Loss Outcome

Starting body weight, age, sex, insulin resistance level, and baseline metabolism all influence the magnitude and speed of weight loss. Patients with higher baseline BMI often lose greater absolute amounts of weight but similar percentages compared to those starting at lower weights. Insulin resistance—common in type 2 diabetes—may initially slow weight loss but improves as medication-driven weight reduction increases insulin sensitivity. Your diet quality, sleep duration, stress levels, and exercise consistency multiply the effect of semaglutide rather than replacing the need for healthy habits.

Medical conditions, medications, and hormone status shape response as well. Hypothyroidism, polycystic ovary syndrome (PCOS), and cortisol dysregulation can blunt weight loss despite consistent semaglutide use. Certain medications (antipsychotics, corticosteroids) promote weight gain and may counteract semaglutide's effect. PlexusDx's comprehensive approach includes assessing these variables alongside genetic testing to refine your personalized protocol and explain realistic timelines specific to your health profile.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How much weight do most people lose on semaglutide in the first month?

First-month weight loss averages 2–5 pounds as appetite begins to decrease and you adjust to lower calorie intake. Significant losses accelerate after 8–12 weeks once your dose reaches therapeutic levels. Individual variation is wide; some patients notice appetite suppression within days, while others take 3–4 weeks to feel the full effect.

Is 15–22% weight loss realistic for everyone on semaglutide?

Clinical trials show 15–22% loss is the average, but individual results range from 5–35% depending on genetics, adherence, diet, and metabolism. Genetic variants identified by the Precision Peptide Genetic Test help predict whether you'll be a rapid responder or experience more gradual weight loss.

Will I regain weight if I stop taking semaglutide?

Studies show 50–70% of lost weight returns within 1–2 years after discontinuation because hunger hormones and appetite signals normalize. Ongoing semaglutide use maintains weight loss, which is why PlexusDx offers affordable, continuous access starting at $149/month with no membership fees.

Can I achieve better weight loss results with oral semaglutide versus injections?

Oral semaglutide (absorbed through the mouth lining) and injected semaglutide show comparable weight loss in clinical studies when dosed appropriately, though injections typically require smaller doses due to better absorption. Injection compliance is often higher because dosing is weekly rather than daily.

How does the Precision Peptide Genetic Test improve my weight loss outcomes?

The Precision Peptide Genetic Test ($99 add-on) analyzes 14 metabolic pathways and identifies variants in GLP1R, GIPR, FTO, and MC4R genes that influence how your body responds to semaglutide.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves